Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Lymphoma Patient Education Forum – Less than One Week Away

On Monday, June 29th the Lymphoma Program at Weill Cornell Medical College invites you to hear from our experts about the latest advances in lymphoma treatment & nutrition:

Patient Edu Flyer Digital 052815

Dr. Lisa Roth Describes a Clinical Trial Testing Nivolumab in Patients with Hodgkin Lymphoma who Relapsed after an Autologous Stem Cell Transplant

In this video Dr. Lisa Roth explains the benefits of a phase II trial for men and women with Hodgkin lymphoma whose disease has relapsed after an autologous stem cell transplant. The purpose of this study is to evaluate the clinical benefits of nivolumab in people with relapsed Hodgkin lymphoma. This trial is sponsored by Bristol-Myers Squibb.

If you’re interested in participating in this trial please call 646-962-2074 for more information. A full listing of Hodgkin lymphoma trials at Weill Cornell Medical College can be found here.

REDLAMP 6: Entecavir vs. Lamivudine in Preventing Hepatitis B Reactivation in Untreated DLBCL

Reactivation of the Hepatitis B virus (HBV) can be a serious and life threatening complication for lymphoma patients who receive rituximab based treatment like R-CHOP. In this video Dr. Jia Ruan explained the results from a randomized phase 3 trial published in JAMA (The Journal of the American Medical Association). In this study researchers compared the effectiveness of Entecavir and lamivudine in preventing HBV reactivation and clinically significant hepatitis in patients with DLBCL, who are receiving R-CHOP.

Previous #REDLAMP entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 646-962-2074.